Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6421704 | 0.83 | ADORA1 (0.48) | ADORA1ESR2NR1H2MAPTKDM4E | |
| SCHEMBL17377231 | 0.83 | ADORA1 (0.48) | ADORA1ESR2NR1H2MAPTKDM4E | |
| SCHEMBL21669695 | 0.81 | ADORA1 (0.39) | ADORA1ESR2NR1H2MAPTKDM4E | |
| SCHEMBL29978414 | 0.80 | ADORA1 (0.46) | ADORA1ESR2NR1H2MAPTKDM4E | |
| SCHEMBL28898349 | 0.80 | HPGD (0.36) | — | |
| SCHEMBL18501717 | 0.79 | ADORA1 (0.53) | ADORA1ESR2NR1H2MAPTKDM4E | |
| SCHEMBL17798700 | 0.79 | EED (0.49) | ADORA1ESR2NR1H2MAPTKDM4E | |
| SCHEMBL21669697 | 0.79 | ADORA1 (0.56) | ADORA1ESR2NR1H2MAPTKDM4E | |
| SCHEMBL29977848 | 0.76 | ADORA1 (0.45) | ADORA1ESR2NR1H2MAPTKDM4E | |
| SCHEMBL25363832 | 0.75 | ADORA1 (0.54) | ADORA1ESR2NR1H2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3830087-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2023-05-24 | — | — | EP | disclosed |
| US-11530227-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | MUTABILIS (FR) | 2022-12-20 | — | — | US | disclosed |
| US-20210277019-A1 | Heterocyclic Compounds And Their Use in Preventing or Treating Bacterial Infections | MUTABILIS (FR) | 2021-09-09 | — | — | US | disclosed |
| WO-2020025587-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277019-A1 | Heterocyclic Compounds And Their Use in Preventing or Treating Bacterial Infections | NQO1, ALPI, LCT | ADORA1 3150/4885ESR2 1860/4885NR1H2 684/4885 |
| US-11530227-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | NQO1, ALPI, LCT | ADORA1 3150/4885ESR2 1860/4885NR1H2 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.